Lichen China Limited Announces Pricing of US$16 Million Initial Public Offering
Lichen China Limited (LICN) announced the pricing of its initial public offering (IPO) of 4,000,000 Class A ordinary shares at $4.00 per share, expected to raise $16 million in gross proceeds. The shares have been approved for listing on the Nasdaq Capital Market and trading is set to begin on February 6, 2023. The Company has also granted underwriters a 45-day option to purchase an additional 600,000 shares. Proceeds will be utilized for expanding financial services, enhancing research and development, improving brand recognition, and general corporate matters. The IPO is led by Univest Securities, LLC as underwriter.
- Expected gross proceeds of $16 million from the IPO.
- Funds will be used to expand services and R&D capabilities.
- Potential dilution from the underwriters' option to purchase an additional 600,000 shares.
The Company expects to receive aggregate gross proceeds of
Proceeds from the Offering will be used to expand the Company's financial and taxation solution services, strengthen research and development ("R&D") capabilities and expand self-developed software, improve brand recognition through multi-channel marketing, and working capital and general corporate matters.
The Offering is being conducted on a firm commitment basis.
A registration statement on Form F-1 relating to the Offering was filed with the
Before you invest, you should read the prospectus and other documents the Company has filed or will file with the
About
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company's proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that the Offering will be successfully completed. Investors can identify these forward-looking statements by words or phrases such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the
For investor and media inquiries, please contact:
Phone: +1 917-609-0333
Email: tina.xiao@ascent-ir.com
View original content:https://www.prnewswire.com/news-releases/lichen-china-limited-announces-pricing-of-us16-million-initial-public-offering-301739365.html
SOURCE
FAQ
What is Lichen China's initial public offering (IPO) details?
When will Lichen China start trading on Nasdaq?
What will the proceeds from the IPO be used for?
Who is the underwriter for Lichen China's IPO?